Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abiomed

This article was originally published in The Gray Sheet

Executive Summary

AbioCor replacement heart will be implanted in five patients to begin initial clinical trial of the destination therapy device, firm announces Jan 30. Endpoints are patient survival and quality of life (1"The Gray Sheet" Jan. 15, 2001, p. 3). While FDA granted an IDE for the implantation, the agency also has required Abiomed to respond to a series of questions within 45 days. Implantation will begin as soon as end-stage heart failure patients can be identified who are at risk for imminent death, are not transplantable and cannot be helped by other therapies

You may also be interested in...



Abiomed Pumps Cash Into Eleventh-Hour Bid For Thermo CardioSystems

Abiomed may be able to leverage its strength in the capital markets - specifically, an enhanced cash position resulting from a $95 mil. secondary offering last March - to undercut a previously announced all-stock bid by Thoratec for ventricular assist device developer Thermo CardioSystems.

Surprise As FDA Approves Sarepta’s Duchenne Drug Vyondys 53

The FDA has overcome doubts about the drug's safety and reversed its decision in just four months.

UK Set For January Brexit After Conservatives Win Election

The Conservative Party's victory in the UK general election means the Brexit withdrawal deal will be able to pass. The UK will leave the EU by 31 January and enter a transition period during which medicines regulation will remain broadly unchanged.

UsernamePublicRestriction

Register

MT014424

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel